Pancreatic Cancer Research

ResearcherChristian-Albrechts-Universität zu KielNo recent work listed

Christian Röder

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7881-9110; OpenAlex author ID A5084129737. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: none · 2023: 1 paper

Papers 9

  1. Monocarboxylate Transporter-1 (MCT1)-Mediated Lactate Uptake Protects Pancreatic Adenocarcinoma Cells from Oxidative Stress during Glutamine Scarcity Thereby P… Co-author DOI 10.3390/antiox12101818↗
  2. Prognostic significance of high mobility group A2 (HMGA2) in pancreatic ductal adenocarcinoma: malignant functions of cytoplasmic HMGA2 expression. Co-author DOI 10.1007/s00432-021-03745-w↗
  3. Topology impacts TRAIL therapy: Differences in primary cancer growth and liver metastasis between orthotopic and subcutaneous xenotransplants of pancreatic duc… Co-author DOI 10.1016/j.hbpd.2021.04.005↗
  4. The expression of death receptor systems TRAIL-R1/-R2/-R4, CD95 and TNF-R1 and their cognate ligands in pancreatic ductal adenocarcinoma. Co-author DOI 10.14670/hh-18-054↗
  5. Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC. Co-author DOI 10.1186/s12885-018-4688-8↗
  6. The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.14768↗
  7. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0094357↗
  8. TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1016/s1499-3872(13)60012-0↗
  9. Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejcb.2010.10.008↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anna Trauzold · 8 shared papers, 2011–2023 · strength 0.84
  2. Holger Kalthoff · 8 shared papers, 2011–2021 · strength 0.68
  3. Christoph Röcken · 4 shared papers, 2014–2021 · strength 0.35
  4. H. Schäfer · 2 shared papers, 2014–2023 · strength 0.23
  5. Susanne Sebens · 2 shared papers, 2014–2023 · strength 0.23
  6. Jan-Paul Gundlach · 2 shared papers, 2018–2021 · strength 0.20
  7. Nourhane Ammar · 1 shared paper, 2023 · strength 0.19
  8. Claudia Geismann · 1 shared paper, 2023 · strength 0.19
  9. Bastian Kettler · 1 shared paper, 2021 · strength 0.17
  10. Friederike Gaertner · 1 shared paper, 2019 · strength 0.11
  11. Shusen Zheng · 1 shared paper, 2017 · strength 0.06
  12. Qi Ling · 1 shared paper, 2017 · strength 0.06
  13. Dong-Hui Zhou · 1 shared paper, 2013 · strength 0.05
  14. Ole Helm · 1 shared paper, 2014 · strength 0.04
  15. Daniela Wesch · 1 shared paper, 2014 · strength 0.04
  16. Bence Sipos · 1 shared paper, 2014 · strength 0.04
  17. Hans‐Heinrich Oberg · 1 shared paper, 2014 · strength 0.04
  18. Lisa Goebel · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.